text,labels
Normal-weight subjects showed significant blood oxygen level-dependent responses in the ventromedial prefrontal cortex ( vmPFC ) to food aromas compared with responses induced by the odor of an inedible object .,3
Female : 35.6 % .,3
"PrEP is efficacious for HIV-1 prevention among women using DMPA and men whose partners use DMPA , suggesting PrEP could mitigate the potential increased HIV-1 acquisition and transmission risks that have been associated with DMPA use .",4
"The SSM 30 g may be an effective , noninvasive alternative to health care provider-administered intravenous , intramuscular , or oral opioids for the management of moderate-to-severe acute pain .",4
"Compared to the odor of a non-edible item, food aromas prompted noteworthy blood oxygen level-dependent (BOLD) responses in the ventromedial prefrontal cortex (vmPFC) among individuals of normal weight.",3
Responses to food aromas in the ventromedial prefrontal cortex (vmPFC) were significantly greater in normal-weight individuals compared to the reactions triggered by the smell of an inedible object.,3
"The ventromedial prefrontal cortex (vmPFC) exhibited substantial blood oxygen level-dependent (BOLD) activity in response to food aromas among subjects with normal body weight, as opposed to the scent of an inedible object.",3
"In individuals of normal weight, the ventromedial prefrontal cortex (vmPFC) displayed significant blood oxygen level-dependent (BOLD) responses when exposed to food aromas, in contrast to the reactions evoked by the odor of a non-edible item.",3
"When compared to the scent of a non-edible object, food aromas elicited notable blood oxygen level-dependent (BOLD) reactions in the ventromedial prefrontal cortex (vmPFC) among subjects with normal body weight.",3
"Subjects with normal weight demonstrated pronounced blood oxygen level-dependent (BOLD) activations in the ventromedial prefrontal cortex (vmPFC) in response to food aromas, as opposed to the responses induced by the scent of an inedible object.",3
The percentage of women is 35.6.,3
35.6% of the population consists of females.,3
Women make up 35.6% of the total.,3
The proportion of females is 35.6%.,3
The female population accounts for 35.6%.,3
Females represent 35.6% of the whole.,3
"PrEP has been proven to be effective for preventing HIV-1 among women who use DMPA and men whose partners use DMPA, indicating a potential role in mitigating the increased risks of HIV-1 acquisition and transmission associated with DMPA use.",4
"The efficacy of PrEP in HIV-1 prevention has been observed in women who use DMPA and men whose partners use DMPA, implying that PrEP could potentially minimize the elevated risks of HIV-1 transmission and acquisition linked to DMPA use.",4
"Among women using DMPA and men with partners on DMPA, PrEP has shown efficacy in preventing HIV-1, suggesting that PrEP could help alleviate the potential risks of increased HIV-1 acquisition and transmission associated with DMPA use.",4
"The effectiveness of PrEP in preventing HIV-1 has been established in women using DMPA and men whose partners use DMPA, indicating that PrEP might mitigate the potential risks of HIV-1 transmission and acquisition associated with DMPA use.",4
"PrEP has proven to be efficacious in preventing HIV-1 among women using DMPA and men whose partners use DMPA, highlighting its potential to mitigate the heightened risks of HIV-1 acquisition and transmission linked to DMPA use.",4
"In women using DMPA and men whose partners use DMPA, PrEP has demonstrated efficacy in HIV-1 prevention, suggesting its potential importance in reducing the associated risks of HIV-1 transmission and acquisition with DMPA use.",4
"The SSM 30 g might offer a viable option for managing moderate-to-severe acute pain, without the need for healthcare providers to administer intravenous, intramuscular, or oral opioids.",4
"Utilizing the SSM 30 g can be an effective and noninvasive approach to managing acute pain of moderate-to-severe intensity, eliminating the requirement for healthcare providers to administer opioids intravenously, intramuscularly, or orally.",4
"The potential effectiveness of the SSM 30 g makes it a promising alternative to healthcare provider-administered intravenous, intramuscular, or oral opioids for treating moderate-to-severe acute pain in a noninvasive manner.",4
"When managing moderate-to-severe acute pain, the SSM 30 g proves to be an efficacious option that eliminates the necessity for healthcare providers to administer opioids intravenously, intramuscularly, or orally.",4
"For the management of moderate-to-severe acute pain, the SSM 30 g can be an efficient and noninvasive alternative, obviating the need for healthcare providers to administer opioids via intravenous, intramuscular, or oral routes.",4
"By employing the SSM 30 g, healthcare providers could potentially replace the administration of intravenous, intramuscular, or oral opioids for the treatment of moderate-to-severe acute pain, offering a noninvasive solution.",4
